Treatment of ANCA-associated vasculitis: New therapies and a look at old entities

Ladan Zand; Ulrich Specks; Sanjeev Sethi; Fernando C. Fervenza

doi:10.1053/j.ackd.2014.01.009

Treatment of ANCA-associated vasculitis: New therapies and a look at old entities

Ladan Zand, Ulrich Specks, Sanjeev Sethi, Fernando C. Fervenza

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.

Original language	English (US)
Pages (from-to)	182-193
Number of pages	12
Journal	Advances in Chronic Kidney Disease
Volume	21
Issue number	2
DOIs	https://doi.org/10.1053/j.ackd.2014.01.009
State	Published - Mar 1 2014
Externally published	Yes

Bibliographical note

Funding Information:
Support: F.C.F. received unrestricted research grants from Genentech/Roche (maker of rituximab); U.S. received money from Genentech/Roche for research grant and consulting (money to institution); L.Z. and S.S. have no relevant financial interests.

Keywords

ANCA-associated vasculitis
Cyclophosphamide
Rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1053/j.ackd.2014.01.009

OpenUrl availability

Full text

Cite this

@article{0d5b40c4f0cf469eaf381c9d8742795b,

title = "Treatment of ANCA-associated vasculitis: New therapies and a look at old entities",

abstract = "Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.",

keywords = "ANCA-associated vasculitis, Cyclophosphamide, Rituximab",

author = "Ladan Zand and Ulrich Specks and Sanjeev Sethi and Fervenza, {Fernando C.}",

note = "Funding Information: Support: F.C.F. received unrestricted research grants from Genentech/Roche (maker of rituximab); U.S. received money from Genentech/Roche for research grant and consulting (money to institution); L.Z. and S.S. have no relevant financial interests. ",

year = "2014",

month = mar,

day = "1",

doi = "10.1053/j.ackd.2014.01.009",

language = "English (US)",

volume = "21",

pages = "182--193",

journal = "Advances in Chronic Kidney Disease",

issn = "1548-5595",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment of ANCA-associated vasculitis

T2 - New therapies and a look at old entities

AU - Zand, Ladan

AU - Specks, Ulrich

AU - Sethi, Sanjeev

AU - Fervenza, Fernando C.

N1 - Funding Information: Support: F.C.F. received unrestricted research grants from Genentech/Roche (maker of rituximab); U.S. received money from Genentech/Roche for research grant and consulting (money to institution); L.Z. and S.S. have no relevant financial interests.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.

AB - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.

KW - ANCA-associated vasculitis

KW - Cyclophosphamide

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84896900502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896900502&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2014.01.009

DO - 10.1053/j.ackd.2014.01.009

M3 - Review article

C2 - 24602467

AN - SCOPUS:84896900502

SN - 1548-5595

VL - 21

SP - 182

EP - 193

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

IS - 2

ER -

Treatment of ANCA-associated vasculitis: New therapies and a look at old entities

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this